0001641226-21-000003.txt : 20210824 0001641226-21-000003.hdr.sgml : 20210824 20210824162741 ACCESSION NUMBER: 0001641226-21-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210824 DATE AS OF CHANGE: 20210824 EFFECTIVENESS DATE: 20210824 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OcuTerra Therapeutics, Inc. CENTRAL INDEX KEY: 0001641226 IRS NUMBER: 274249384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-398986 FILM NUMBER: 211202472 BUSINESS ADDRESS: STREET 1: 85 E. INDIA ROW STREET 2: SUITE 21G CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 339-234-1333 MAIL ADDRESS: STREET 1: 85 E. INDIA ROW STREET 2: SUITE 21G CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: SciFluor Life Sciences, Inc. DATE OF NAME CHANGE: 20150504 D/A 1 primary_doc.xml X0708 D/A LIVE 0001641226 OcuTerra Therapeutics, Inc. 85 E. INDIA ROW SUITE 21G BOSTON MA MASSACHUSETTS 02110 339-234-1333 DELAWARE SciFluor Life Sciences, Inc. Corporation true David Scott Edwards 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Executive Officer Promoter William H. Koster 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Director Robert Dempsey 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Director Robert Ruffolo 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Director Robin Steele 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Director Kerrie Brady 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Executive Officer Director Brent Saunders 85 E. India Row Suite 21G Boston MA MASSACHUSETTS 02110 Director Pharmaceuticals Decline to Disclose 06b true 0001641226-21-000002 2021-04-27 false true true true false 0 Maxim Group LLC 120708 None None 405 Lexington Avenue New York NY NEW YORK 10174 All States false 50000000 31525965 18474035 false 226 4867500 true 0 true Maxim to receive 10% (5% for certain investors introduced by issuer) cash fee of total offering amount less $1,325,000 in converted notes, and 10% common stock warrant coverage. 5525000 true false OcuTerra Therapeutics, Inc. /s/ D. Scott Edwards D. Scott Edwards Chief Development Operations Officer 2021-08-24